Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24130455 | 0.75 | ALDH1A1 (0.43) | MAPTALDH1A1SMN1; SMN2GAALMNA | |
| SCHEMBL2868944 | 0.73 | ALDH1A1 (0.47) | HTTMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL476708 | 0.73 | HTT (0.46) | HTTMAPTALDH1A1POLBLMNA | |
| SCHEMBL476671 | 0.71 | ALDH1A1 (0.42) | MAPTALDH1A1POLBSMN1; SMN2GAA | |
| SCHEMBL15803828 | 0.71 | HTT (0.47) | HTTMAPTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13139569 | 0.70 | ALDH1A1 (0.44) | MAPTALDH1A1POLBSMN1; SMN2LMNA | |
| SCHEMBL14876425 | 0.70 | ALDH1A1 (0.47) | HTTMAPTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3593138 | 0.70 | GAA (0.53) | MAPTALDH1A1SMN1; SMN2GAAMEN1 | |
| SCHEMBL476589 | 0.69 | CNR2 (0.48) | MAPTALDH1A1POLBSMN1; SMN2NPY5R | |
| SCHEMBL476549 | 0.69 | CNR2 (0.48) | MAPTALDH1A1POLBSMN1; SMN2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951225-B1 | 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-7741363-B2 | 3-Acylindole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275102-A1 | 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | F12, ECI1, NQO2 | HTT 1044/4885MAPT 3394/4885ALDH1A1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.